Tadalafil Tablet, Film Coated
Product Images NDC 60219-1347

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 60219-1347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 (Tadalafil Tablets Usp 1)

Chemical structure diagram of Tadalafil, a human prescription drug active ingredient shown as a molecular formula with rings and bonds representing its chemical composition.*

FDA Label Image

2.5 mg Label (Tadalafil Tablets Usp 10)

Label for Tadalafil Tablets, USP 2.5 mg oral film-coated tablets by Amneal Pharmaceuticals LLC. The label indicates a 30 tablet count for once daily use, includes storage instructions, dosage caution, and distributor information located in Bridgewater, NJ. The label also features a barcode and printing information.*

FDA Label Image

5 mg Label (Tadalafil Tablets Usp 11)

Tadalafil Tablets USP 5 mg film-coated tablets in a 30-tablet container. The label states the tablets should not be split and the entire dose should be taken. Distributed by Amneal Pharmaceuticals LLC, Bridgewater, NJ. Includes storage instructions and a barcode.*

FDA Label Image

10 mg (Tadalafil Tablets Usp 12)

Label for Tadalafil Tablets, USP 10 mg, film-coated tablets in a 30 count package by Amneal Pharmaceuticals LLC. The label includes dosage strength, a note that tablets should not be split, storage instructions, and distributor information. There is a barcode and a pill imprint visible on the label.*

FDA Label Image

20 mg Label (Tadalafil Tablets Usp 13)

Tadalafil Tablets USP 20 mg film-coated tablets packaging label with NDC 60219-1349-3. This label features a purple highlighted strength, a small tablet image with imprint 09, and indicates 'Rx only' and '30 Tablets'. Distributed by Amneal Pharmaceuticals LLC, Bridgewater, NJ. Storage instructions and dosage warnings are included.*

FDA Label Image

10 (Tadalafil Tablets Usp 2)

A set of four line graphs comparing the difference in blood pressure (difference between Tadalafil and placebo, measured in mmHg) over time in hours for standing and supine positions. The graphs display standing systolic blood pressure, standing diastolic blood pressure, supine systolic blood pressure, and supine diastolic blood pressure over a 96-hour period with error bars indicating variability.*

FDA Label Image

10 (Tadalafil Tablets Usp 3)

A dual line chart showing the effects on systolic blood pressure over 24 hours post-dose, comparing Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The top graph displays standing systolic blood pressure changes, and the bottom graph shows supine systolic blood pressure changes over time in hours.*

FDA Label Image

10 (Tadalafil Tablets Usp 4)

A line graph showing the change in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. Four data series compare 20 mg tadalafil and placebo at 8:00 and 20:00 time points, each with 8 mg daily doxazosin. The x-axis represents time in hours after drug administration, and the y-axis indicates systolic blood pressure changes.*

FDA Label Image

10 (Tadalafil Tablets Usp 5)

A pharmacokinetic graph showing plasma tadalafil concentration (mcg/L) over time (hours) for different dosing regimens. The graph compares a single 20 mg tadalafil dose, a single 5 mg tadalafil dose, and a once-daily 5 mg tadalafil dose following 5 consecutive days of administration, with time on the x-axis and plasma concentration on the y-axis.*

FDA Label Image

10 (Tadalafil Tablets Usp 6)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between Tadalafil 5 mg and placebo. The x-axis represents the duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows the change from baseline. The graph shows a greater decrease in score with Tadalafil 5 mg compared to placebo, indicating a treatment effect, with a noted statistical significance (p<0.01).*

FDA Label Image

10 (Tadalafil Tablets Usp 7)

Line graph showing change from baseline in IPSS total score over 12 weeks of treatment, comparing Tadalafil 5 mg and placebo. The graph displays greater reduction in scores for Tadalafil 5 mg at weeks 4, 8, and 12 with statistical significance indicated at weeks 4 and 12 (p<0.01).*

FDA Label Image

10 (Tadalafil Tablets Usp 8)

A line graph showing the least squares (LS) mean change from baseline over 0, 4, 12, and 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph includes markers for statistical significance at weeks 4, 12, and 26, with Tadalafil/Finasteride showing greater improvement (more negative change) than Placebo/Finasteride.*

FDA Label Image

10 (Tadalafil Tablets Usp 9)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil 5 mg versus placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in IPSS score. Tadalafil 5 mg shows a greater reduction from baseline over time compared to placebo, with statistical significance noted at 12 weeks (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.